JPMorgan Chase & Co. Has $10.72 Million Stock Holdings in Harrow, Inc. (NASDAQ:HROW)

JPMorgan Chase & Co. lifted its holdings in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 443.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 238,367 shares of the company's stock after buying an additional 194,480 shares during the quarter. JPMorgan Chase & Co. owned about 0.67% of Harrow worth $10,717,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in Harrow by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock worth $57,000 after acquiring an additional 227 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Harrow by 5.0% during the second quarter. The Manufacturers Life Insurance Company now owns 11,865 shares of the company's stock worth $248,000 after purchasing an additional 567 shares during the period. Quest Partners LLC bought a new stake in Harrow in the third quarter valued at about $29,000. Hills Bank & Trust Co acquired a new position in Harrow in the third quarter valued at about $107,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Harrow by 64.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 6,825 shares of the company's stock worth $307,000 after buying an additional 2,668 shares during the last quarter. 72.76% of the stock is owned by institutional investors.

Analysts Set New Price Targets

HROW has been the subject of several recent analyst reports. Lake Street Capital upped their target price on shares of Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a research note on Friday, October 4th. Craig Hallum lifted their price target on shares of Harrow from $45.00 to $65.00 and gave the company a "buy" rating in a research note on Friday, October 4th. Finally, B. Riley lowered their target price on Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a report on Wednesday, December 4th.

Harrow Stock Performance

HROW opened at $35.83 on Monday. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -38.12 and a beta of 0.72. Harrow, Inc. has a 12-month low of $9.13 and a 12-month high of $59.23. The business has a 50 day moving average of $39.58 and a 200-day moving average of $38.48.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.